Adverse Event Case Narratives & Causality Assessment
Generate audit-ready adverse event narratives with ICH-GCP causality assessment
What You Can Do
You can rapidly document adverse events with rigorous causality assessment, ensuring consistent safety reporting across sites and phases. The skill guides you through seriousness evaluation, temporal relationship analysis, and evidence-based narrative writing that satisfies regulatory audits and eCTD submission requirements. You'll generate safety documentation that protects trial integrity while accelerating your safety monitoring workflow.
Features
Categorize events by seriousness, expectedness, and temporal relationship to study drug or protocol procedures
Apply WHO-UMC, ICH E2A, or sponsor-specific algorithms consistently across all case narratives
Draft audit-ready case summaries using ICH/FDA terminology and formatting for eCTD submissions
Identify patterns across multiple events or sites that warrant escalation or expedited reporting
Prepare expedited safety reports with 24-48 hour turnaround for critical events
Resolve conflicts between investigator causality judgments and medical/scientific evidence
Validate AE narratives against audit standards before submission to regulatory bodies
Adapt causality logic and reporting format to phase-specific regulatory expectations
Example Output
Example 1: Grade 3 Hypertension – Suspected Related
Adverse Event: Hypertension (Grade 3, Serious, Unexpected)
Case Narrative: Patient XYZ, 58M, enrolled Day 1 on Study ABC-001, Test Drug 100mg BID. Baseline BP 135/82 mmHg. On Study Day 14, patient reported headache and dizziness at clinic visit; BP measured 178/105 mmHg. No prior hypertension history. Temporal relationship strong (13 days post-initiation). ECG normal, urinalysis negative. Investigator assessed "Probably Related." ASSESSMENT: Consistent with known pharmacology of test drug (α-adrenergic effects). WHO-UMC classification: Probable. Recommendation: Continue with antihypertensive co-medication per protocol, intensify BP monitoring.
Example 2: Hospitalization for Gastroenteritis – Unrelated
Adverse Event: Gastroenteritis with dehydration (Grade 3, Serious, Expected)
Case Narrative: Patient ABC, 42F, enrolled Day 8 on Study XYZ-202, Placebo arm. On Study Day 26, presented to hospital ED with 2-day history of diarrhea/vomiting. Stool culture positive for Salmonella (source: contaminated food at family gathering Day 23, before symptom onset). Received IV fluids, discharged Day 27. Test drug exposure: none (placebo). ASSESSMENT: Clear epidemiological link to foodborne pathogen; temporal relationship inconsistent with study drug (patient in placebo arm). WHO-UMC classification: Unrelated. No further action required beyond routine safety reporting.
What's Included
- SKILL.md instruction file with causality frameworks (WHO-UMC, ICH E2A) and regulatory compliance checklists:
- AE Intake Template: Structured form capturing demographics, event details, and temporal relationship
- Causality Assessment Worksheet: Step-by-step algorithm to guide sponsor/investigator causality determination
- Case Narrative Template: Regulatory-compliant structure for serious/unexpected/expedited reports
- Safety Signal Detection Checklist: Pattern recognition matrix for multi-site events requiring escalation
- eCTD Safety Update Format Guide: Formatting rules for FDA/EMA submissions
Who It's For
- Clinical Research Associates (CRAs) — Primary users conducting site monitoring and AE assessment
- Clinical Trial Coordinators — Document safety events and maintain eCTD packages
- Medical Safety Officers — Review investigator assessments and validate causality determinations
- Regulatory Affairs Specialists — Format AE narratives for eCTD submissions and agency submissions
- Pharmacovigilance Managers — Identify safety signals and escalate serious/unexpected events
Best For
- Documenting serious adverse events in Phase I-III trials with consistent causality logic
- Reconciling conflicting investigator assessments with scientific evidence
- Preparing expedited safety reports (24-48 hour turnaround) for regulatory notification
- Conducting pre-audit AE documentation reviews and completeness validation
- Escalating safety signals from pattern recognition across multiple sites or cohorts
You might also like
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-w
You can architect end-to-end bioinformatics analysis pipelines by translating your research question into algorithmic approaches, selecting and optimizing appropriate tools and parameters for your dataset, and validating results against biological expectations. This skill guides you through the complete decision tree from raw data to publication-ready interpretation, helping you avoid parameter overfitting, misinterpreted statistical thresholds, and algorithm selection errors that compromise research validity.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
Conduct comprehensive job risk assessments in minutes, generate detailed task analysis reports with biomechanical findings, and develop prioritized ergonomic interventions backed by OSHA and NIOSH guidelines. You'll identify risk factors, quantify hazard severity, and produce actionable recommendations that reduce worker injury rates and improve compliance documentation.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can design experiments with appropriate controls, replicate structures, and sample sizes before conducting any bench work. This skill helps you establish clear endpoints, identify confounding variables, select the right statistical tests, and create reproducible data collection protocols—preventing costly failed experiments and increasing publishability.
by kody-w